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Nodular glomerulosclerosis results from increased deposition
of extracellular matrix proteins and monotypic light chains.
The inability of mesangial cells to degrade abnormal levels of
tenascin-C—along with the increased expression of some
growth factors such as platelet-derived growth factor (PDGF)
and transforming growth factor-b (TGF-b)—is crucial to the
pathogenesis of light chain deposition disease (LCDD). In
order to study the molecular processes contributing to LCDD,
we grew mesangial cells in three-dimensional matrices and
incubated the cells with free light chains purified from the
urine of patients with biopsy-proven LCDD, immunoglobulin-
associated amyloid deposits, or myeloma cast nephropathy.
Light chains of the latter two cohorts served as controls.
Mesangial cells incubated with light chains from patients
with LCDD show a significant increase in tenascin-C
expression, centrally located within newly formed nodules,
along with increased expression of PDGF and TGF-bs,
compared to mesangial cells incubated with control light
chains. There was less extracellular MMP-7 even though its
intracellular expression is markedly increased compared to
the control. Addition of active MMP-7 degraded this excess
tenascin-C in vitro, a process that could be prevented by an
exogenous MMP inhibitor. Our in vitro model recapitulates
in vivo findings in patients with LCDD, thus allowing
definition of the sequential pathologic processes associated
with glomerulopathic light chain interactions with mesangial
cells.
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Light chain deposition disease (LCDD) is one manifestation
of monoclonal immunoglobulin deposition in the kidney,
first reported in 19731 and later confirmed by Randall et al.2
The incidence of LCDD in patients with plasma cell dyscrasia
is approximately 5%.3–5 It is characterized by the presence of
immunoglobulin components (light chains) deposits that are
neither fibrillar nor Congo red positive. Ultrastructurally, the
deposits are seen as punctate granular electron-dense
material, which is typically present in the subendothelial
glomerular areas and in the mesangium, and may also be
present in other renal compartments.3,6 Clinical manifesta-
tions of LCDD are varied and may include nephrotic
syndrome (in less than 30% of patients), progressive renal
insufficiency (in approximately 70% of patients), and
hypertension (in more than 80% of the patients)7 among
others.
Nodular glomerulosclerosis, the classically described
lesion in LCDD, is preceded by other morphological
manifestations, including mesangial and membranoproli-
ferative patterns.8,9 The mesangial nodularity within the
glomerulus results from the combined increased deposition
of extracellular matrix (ECM) proteins mixed with mono-
typic light chain deposits, most commonly kappa (k).
Thickening of the glomerular peripheral capillary walls and
tubular basement membranes results from the deposition of
these monotypic light chains (LCs). Vascular deposits of
monotypical LCs can also occur. The role of mesangial cells
has been found to be critical in the pathogenesis of
glomerulosclerosis.3,10,11
The interaction of mesangial cells with LCDD-LCs engages
the autocrine activation of growth factors, such as platelet-
derived growth factor-b (PDGF-b) and transforming growth
factor-b (TGF-b).10,11 These cells are stimulated initially by
PDGF-b to proliferate, resulting in mesangioproliferative and
membranoproliferative variants of LCDD. Increased matrix
production and deposition of ECM proteins, such as type IV
collagen, laminin, fibronectin, and, most importantly,
tenascin-C,10,11 under the influence of TGF-b in the later
phases of the glomerulopathy, characterize LCDD (Figure 1).
Apoptosis of mesangial cells accompanies glomerulosclero-
sis12 and has been shown to be enhanced by glomerulopathic
LCs.13 Work performed on renal biopsies from patients with
LCDD has supported a role for PDGF-b and TGF-b in the
pathogenesis of this disorder,14 although how these growth
factors actually participate in the overall pathogenesis of this
disease has remained unclear.
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The tenascins are a family of large oligomeric glycopro-
teins found in the ECM of vertebrate animals.15 Tenascin is a
cell adhesion molecule, which interacts with integrins,
collagens, proteoglycans, and fibronectin.16 They possess
highly conserved sequences with the heptad repeats allowing
them to assemble into timers or hexamers.17 Tenascin-
cytotactin was the first member of the family to be
described18 and exist in a hexabrachion19–21 or octopus-like
configuration. Splice variants of tenascin-C have been
described,22 with as many as 27 different mRNA variants
identified in the developing mouse brain.22 Subsequently,
four other members were described, namely TN-R, TN-W,
TN-X, and TN-Y.
Tenascin-C has been identified in a number of patholo-
gical conditions, including breast carcinomas,23 keloids,24
diabetic neuropathy,25 pulmonary fibrosis,26 and occupying
the central areas of the mesangial nodules in LCDD and AL-
amyloidosis (AL-Am) in the remaining mesangial matrix.8,27
Its primary function has not been described; however, its
presence in non-degradable fibrotic and sclerotic tissues
suggests a fundamental role for this protein in progressive,
difficult to reverse back to irreversible pathological processes.
Matrix metalloproteinase-7 (MMP-7), also known as
matrilysin-1, is a hydrolytic protease belonging to the
minimal domain group of human MMPs.28 It is secreted as
a pro-enzyme (proMMP-7) and is later activated by other
MMPs or proteins29–31 in a proteolytic cascade similar to the
coagulation and thrombolytic systems in humans. Like other
MMPs (Matrixins), it is a zinc-dependent endopeptidase
involved in the regulation of ECM proteins.32–38 It is made up
of only three domains, namely a pre, pro, and catalytic zinc-
containing domain. Although MMP-7 is capable of degrad-
ing and modulating several ECM proteins,31,39,40 it has been
shown to be the MMP most actively involved in the
catabolism of tenascin.41–43
A previous paper addressed the overall role of MMPs in
mesangial remodeling in AL-Am and LCDD.38 In situ
zymographic studies have demonstrated changes in MMPs
and tissue inhibitor of metalloproteinases in the glomerular
and interstitial renal compartment on tissue sections44 that
are consistent with fibrotic phenotype in LCDD. This paper
expands on studies reported earlier and provides a unified
and comprehensive understanding of the pathogenesis of
LCDD.
This paper reports an in vitro model, which allowed the
dissection of sequential pathologic processes that take place
as glomerulopathic LCs interact with mesangial cells in
LCDD.
Although in vitro events do not always accurately
reflect in vivo events, this system has provided meaningful
insights of clinical significance and has become an important
research platform for understanding the pathogenesis of this
disease.
RESULTS
Morphology of mature lesion in LCDD
Hematoxylin and eosin (H&E) staining of mature LCDD
glomerular lesions showed characteristic mesangial nodular
lesions and variable thickening of the peripheral capillary
walls (Figure 2a). These nodules exhibited rather striking
argyrophilia in most instances with Jones’ silver methanamie
stain (Figure 2b), central deposition of tenascin-C (Figure
2c), and peripheral deposition of collagen IV (Figure 2d).
Ultrastructurally, punctate granular electron-dense material
is present in the expanded mesangial areas (Figure 2e)
corresponding to monoclonal light chain deposits.
'Minimal change'
glomerulopathy
Sclerosing
glomerulopathy
Membrano-proliferative-
like glomerulopathy
Crescentic
 glomerulopathy
PBGF-β
a b
d
c
PBGF-β
TGF-β
TGF-β
Mesangial proliferative
glomerulopathy
Nodular glomerulopathy
Figure 1 | Sequential glomerular changes associated with light chain deposition disease at different stages of disease process.
Note the influences of PDGF-b and TGF-b at the different stages of the lesion. PDGF-b drives proliferation of the mesangial cells (a,b,c),
whereas TGF-b is responsible for protein deposition and nodule formation (c,d).
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PDGF-b and TGF-b expressions in conditioned media
PDGF-b expression was analyzed in conditioned media
obtained from human mesangial cells (HMCs) grown in
three-dimensional (3D) Matrigel using an indirect ELISA
technique. There were significantly increased expressions of
PDGF-b in LCDD-LC-conditioned media over time as
compared with AL-LC (Figure 3). Similar findings were
noted for TGF-b (Figure 4).
Collagen IV and tenascin-C expressions in 3D Matrigel
Mesangial cells (MCs) treated with LCDD showed three times
more nodules as compared with controls (Figure 5a)
(Table 1). It was noted that cells treated with LCDD-LCs
alone showed the highest expressions of tenascin-C com-
pared with the other treatment conditions and controls
(Figure 5b). Collagen IV expression was markedly increased
in all the LCDD treatment conditions as compared with
controls (Figure 5b). HMCs grown in two-dimensional
culture on Matrigel showed similar growth pattern and
deposition of tenascin-C (Figure 6c).
Tenascin-C expression in dissected nodules
MC nodules were dissected from Matrigel and proteins
harvested. Indirect ELISA assay for tenascin-C showed
statistically significant differences between LCDD-LC, AL-LC-
treated cells, and controls. LCDD-LCþMMP-7þ inhibitor-
treated cells showed statistically significant higher amounts of
tenascin-C (Figure 7).
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Figure 2 | Mature LCDD glomerulopathy. Nodular lesion of LCDD.
(a) H&E stain, strong agyrophilic staining of nodules. (b) Jones
methylamine sliver stain, tenascin-C expression in the center of
nodules. (c) Immunohistochemistry using DAB with imidiazole
enhancement and methyl green pynonine as counterstain,
collagen IV expression at the periphery of nodules and (d)
immunohistochemistry using DAB as chromogen are shown (original
magnification  400), and punctate LC deposits in the mesangium
(e) uranyl acetate and lead citrate original magnification  6000.
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Figure 3 | PDGF-b expression in conditioned media obtained
from HMCs treated with different types of light chains and
controls. Results are the mean±s.d. of duplicate samples.
Statistically significant differences were observed between
AL-LC- and LCDD-LC-treated cells at a significance of Po0.05.
* Indicates AL samples at 4 days versus other time points; # indicates
LCDD samples at 4 days versus other time points; & indicates LCDD
samples at 8 days versus 12 and 16 days time points; and $ indicates
LCDD samples at 12 days versus 16 days time points.
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Figure 4 | TGF-b expression in conditioned media obtained
from HMCs treated with different types of light chains and
controls. Results are the mean±s.d. of duplicate samples. Note
statistically significant differences observed between controls, AL-
LC-, and LCDD-LC-treated cells at a significance of Po0.05. @
Indicates control cells at various time points; * indicates AL
samples at 4 days versus other time points; # indicates LCDD
samples at 4 days versus other time points; & indicates LCDD
samples at 8 days versus 12 and 16 days time points; and $
indicates LCDD samples at 12 days versus 16 days time points.
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MMP-7 and tenascin-C gene expressions in dissected nodules
Gene expressions of MMP-7 and tenascin-C were observed
in nodules dissected from Matrigel using a quantitative
reverse transcriptase PCR. The highest levels of MMP-7
mRNA were noted in AL-LC-treated cells as compared
with significantly lower levels in LCDD-LC-treated cells
and controls (Figure 8a). Tenascin-C mRNA levels
were significantly higher in LCDD-LC-treated cells as
compared with AL-LC-treated cells and controls
(Figure 8b).
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Figure 5 | Nodule formation in Matrigel matrix. (a) Note approximately two times increase in nodule formation in LCDD-LC-treated
cells compared with controls after 20 days incubation. Samples stained for collagen IV using DAB as chromogen, original magnification
 100. (b) Collagen IV and tenascin-C expressions in HMC nodules under different treatment conditions. Note increased central location
tenascin-C expressions in LCDD-LC- and LCDD-LCþMMP-7þ inhibitor-treated cells compared with controls and decreased tenascin-C
expressions in LCDD-LCþMMP-7 and LCDD-LCþ inhibitor-treated cells compared with controls, original magnification  400. Collagen IV
expressions are also increased in LCDD-LC treatment conditions as compared with controls. Lambda light chains are deposited in the
central areas of the nodules of LCDD-LC cells, whereas controls show no deposits using DAB as chromogen, immunohistochemistry original
magnification  400.
Table 1 | Description and grading of human mesangial nodules formed in Matrigel matrix, and an evaluation of the nodules for
tenascin-C and collagen IV expressions
Tenascin-C (nodules) Collagen IV (nodules)
Category Matrigel integrity Number of nodules Periphery Center Periphery Center
Control Good X 1+ 1+ 2+ 1+
AL Poor/destroyed NA NA NA NA NA
LCDD Good 2 1+ 3+ 3+ 2+
LCDD+MMP-7 Good 2 0 1+ 2+ 3+
LCDD+inhibitor Good 3 0 2+ 3+ 1+
LCDD+MMP-7+inhibitor Good 5 1+ 3+ 3+ 2+
LCCD, light chain deposition disease; MMP-7, matrix metalloproteinase-7.
Cells were incubated under different treatment conditions and harvested at 20 days after treatment. Samples were graded for immunohistochemical staining of the centers
and periphery of the nodules in 10 fields at  20 objective for both tenascin-C and collagen IV expressions.
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Collagen IV and tenascin-C expressions in glomeruli
Renal glomeruli were immunohistochemically stained for
collagen IV and tenascin-C expressions (Figure 9a). Sig-
nificant differences were noted in tenascin-C protein
expressions among the AL and LCDD cases (Figure 9b).
LCDD cases expressed three times more tenascin-C and two
times more collagen IV than the AL cases.
MMPs in HMCs
Only MMP-7 was expressed in cells, with LCDD-LC-treated
cells expressing the most compared with AL-LC-treated cells
and controls (Figure 10a). Active MMP-1, -3, and -7 were
detected in the conditioned media of HMCs treated with LCs
and controls. AL-LC-treated cells showed an enhanced
expression of all MMPs, whereas LCDD-LC-treated cells
showed an inhibited expression of MMP-7 in the conditioned
media as compared with other treatment conditions (Figure
10b).
MMP-7 and tenascin-C expressions in HMCs
Tenascin-C expression was highest in LCDD-LC-treated cells
as compared with other LC-treated cells and controls (Figure
11a). The addition of 10 mg/ml of purified tenascin-C with
LCs and medium to HMCs enhanced MMP-7 expression in
all conditions. However, cells treated with AL-LCs showed the
least amount of tenascin-C, whereas LCDD-LC-treated cells
showed the highest expression of tenascin-C (Figure 11b)
(Tables 2 and 3).
DISCUSSION
Significant advances in elucidating the pathogenesis of LCDD
have taken place in the last 32 years since this entity was
described. Translation of basic and clinical research efforts into
a better overall appreciation of the disease process represents
the next logical step to achieve a comprehensive molecular
understanding. Basic and clinical research data have not been
collated into a unified vision, providing a molecular under-
standing of LCDD as a model of glomerulosclerosis.
Initial interactions of circulating glomerulopathic light
chains (GLCs) occur with the subendothelium. These LCs are
detected subendothelially in the glomeruli using ultrastruc-
tural labeling techniques in the lesion that has been referred
to as the ‘minimal change lesion’ in patients with underlying
plasma cell dyscrasias, because the only identifiable morpho-
logic finding associated with the glomeruli in these cases at
the light and immunomicroscopic level is effacement of the
foot processes of the visceral epithelial cells.3 This lesion
occurs in patients with nephrotic-range proteinuria with
large amounts of albumin (not only monotypical LCs) as a
component of the proteinuria. Proteinuria results from the
M
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Figure 6 | HMCs grown on Matrigel matrix (M) using two-dimensional technique. Single monolayer with little proliferation of cells when
treated with tubulopathic light chains (a), H&E staining of nodule formed by MCs treated with LCDD light chains (b), and H&E and the
expression of tenascin-C in the center of nodule formed by MCs treated with LCDD light chains (c). DAB as chromogen, original
magnification  400.
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Figure 7 | Tenascin-C expression in mesangial cell nodules
cultured in Matrigel matrix showing statistically significant
differences between AL-LC, LCDD-LC, LCDD-LCþMMP-
7þ inhibitor, and control conditions at a significance of
Po0.05. Note that all LCDD-LC combinations showed higher
expressions of tenascin-C in the extracted nodules compared with
AL-LC and controls. Results are the mean±s.d. of duplicate
samples. * Indicates control cells versus other treatment
conditions; @ indicates AL-LC-treated cells versus all LCDD-LC
conditions; # indicates LCDD-LC-treated cells versus other LCDD
treatment conditions; and $ indicates LCDDþ inhibitor-treated
cells versus LCDDþMMP-7þ inhibitor.
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loss of the glomerular basement membrane permeability. It is
not until the monotypic LCs reach the mesangium that
mesangial homeostasis is altered and the production of
growth factors by MCs takes place, resulting in the sequence
of events shown in Figure 1.
The initial role of (PDGF-b) as a proliferative factor for
mesangial cells is clearly shown in the in vitro model. Both AL
and LCDD-LCs first stimulate PDGF-b secretion and
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Figure 8 | Tenascin-C and MMP-7 mRNA expressions in
mesangial cell nodules cultured in Matrigel matrix. No Ds
showing statistically significant differences between AL-LC, LCDD-
LC, LCDD-LCþMMP-7þ inhibitor, and control conditions at a
significance of Po0.05. (a) Note that all LCDD-LC combinations
showed higher expressions of tenascin-C in the extracted nodules
as compared with AL-LC and controls. Results are the mean±s.d.
of duplicate samples. * Indicates control cells versus other
treatment conditions; @ indicates AL-LC-treated cells versus all
LCDD-LC conditions; # indicates LCDD-LC-treated cells versus
other LCDD treatment conditions; and $ indicates
LCDDþ inhibitor-treated cells versus LCDDþMMP-7þ inhibitor.
(b) MMP-7 mRNA expression in mesangial nodules in Matrigel
matrix as compared with GAPDH amplicon ratio. Statistically
significant differences were observed among the treatment
conditions at a significance of Po0.05. AL-LC-treated cells showed
the highest upregulation of MMP-7 gene as compared with the
LCDD-LC experimental conditions. Results are the mean ± s.d. of
duplicate samples. * Indicates control cells versus other treatment
conditions; @ indicates AL-LC-treated cells versus all LCDD-LC
conditions; # indicates LCDD-LC-treated cells versus other LCDD
treatment conditions; & indicates LCDDþMMP-7 versus
LCDDþ inhibitor and LCDDþMMP-7þ inhibitor; $
LCDDþ inhibitor treated cells versus LCDDþMMP-7þ inhibitor.
St
ai
ni
ng
 in
te
ns
ity
0.00
0.50
1.00
1.50
2.00
2.50
DN
AL
LCDD
Normal
Collagen IV Tenascin-C
Normal AL LCDD DN
P<0.05
*
#&ε
*@$
*@
#
#&
#&ε
*@$
Collagen IV
Tenascin-C
Figure 9 | Collagen IV and tenascin-C expressions in the glomeruli
obtained from renal biopsies of patient with glomerulopathies. (a)
Note significantly higher expressions of collagen IV and tenascin-C
expressions in the glomeruli from LCDD patients as compared with AL
and controls, original magnification  400. (b) Analysis of the staining
patterns showed significant differences at a significance of Po0.05 in
the expressions of both collagen IV and tenascin-C among the study
groups. AL samples showed significantly lower expressions of both
collagen IV and tenascin-C compared with LCDD samples. Results are
the mean±s.d. of duplicate scores. * Indicates collagen IV in normal
tissues versus collagen IV other tissues; @ indicates collagen IV in AL
tissues versus LCDD and DN tissues; $ indicates collagen IV in LCDD
tissues versus DN tissues; # indicates tenascin-C in normal tissues versus
other tissues; & indicates tenascin-C in AL tissues versus LCDD and DN
tissues; and e indicates tenascin-C in LCCD tissues versus DN tissues.
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activation of mesangial cells, followed by TGF-b. The direct
effect of PDGF-b results in MC proliferation, whereas that of
TGF-b in increased mesangial matrix production and
deposition, the latter a manifestation of LCDD and not of
AL-Am. Once TGF-b is stimulated in these cells, an
inhibitory effect on PDGF-b, and thus cell proliferation, is
controlled. The in vitro model recapitulates the in vivo
morphologic expressions of LCDD seen in renal biopsies
from these patients (Figures 1 and 5). The mesangial cell
proliferation and nodularity seen in LCDD are attributed to
the action of both cytokines. If PDGF-b secretion predomi-
nates, mesangial and membranoproliferative-like prolifera-
tive morphologic manifestations will be present, and as TGF-
b becomes active, matrix deposition leading to mesangial
nodularity occurs, creating the pattern of nodular glomer-
ulosclerosis.
Tenascin-C is the main ECM protein that is deposited in
mesangial nodules (Figures 2c, 5a and b, and 9a) in the
mature stages of LCDD. The mechanism responsible for
tenascin-C deposition in the mesangial nodules and failed
degradation is intriguing. Tenascin-C monomers have been
estimated to be over 300 kDa,45 with 14.5 EGF-like repeats
and 8 fibronectin type III allowing it to bind other ECM
components, such as the integrins, heparin, collagens,
proteoglycans, and fibronectin. Consequently, cell interac-
tions with tenascin-C are quite complex. It is possible that
anchorage of these normal cell adhesion molecules to the
arms of the tenascin-C molecule slows proteolytic activity of
MMP-7 allowing for the tenascin-C molecule to remain
buried in the center of the mesangial nodules, making its
removal difficult. In addition, this might explain the presence
of collagen IV at the periphery of these nodules seen in
Figures 2d, 5b, and 9a. The fact that tenascin-C is abundantly
produced in disease conditions such as LCDD may provide a
hint to its functions. What has been noticed in our in vitro
model experiments is the colocalization of tenascin-C and
LCDD-LCs in the center of the mesangial cell nodules (data
not shown). Degradation studies by Imai et al.41 and Siri
et al.43 have successfully proven the ability of MMP-7 to
degrade tenascin-C, but only after 24 h incubation at 371C.
This suggests the hardiness of the tenascin-C molecule to
resist degradation. Alterations in the production and
secretion of MMP-7 may also be important factors in
potentiating tenascin accumulation.
The phenotypically changed mesangial cells (myofibro-
blasts) secrete tenascin-C in abundance (Figure 11). LCDD-
LCs cannot be catabolized in the mesangial cells, likely
because of their physicochemical characteristics. As a result,
they become trapped in the ECM admixed with deposited
tenascin-C. It is known that tenascin-C inhibits cell
adhesion,16,42 and it also inhibits cell proliferation initiated
by growth factors or by the tumor promoter phorbol 12-
myristate 13-acetate (PMA).46 In addition, it has been shown
that MMP-7 expression in the conditioned media obtained
from culturing mesangial cells with LCDD-LCs is signifi-
cantly decreased (19) compared with controls in in vitro
studies, and only accounts for approximately 2% of total
MMPs secreted by these cells as compared with 22% in
control cells.47
In vitro experiments designed to test the hypothesis of
MMP-7 and tenascin-C roles in the progression of LCDD
have revealed some interesting findings. MCs overproliferate
(3 ) in the presence of LCDD-LCs as compared with
controls (Figure 5a). If exogenous active MMP-7 is added to
LCDD-LC in culture media and incubated with these cells,
there is a significant decrease in tenascin-C expression in the
nodules as compared with the LCDD-LC-treated cells, and
there is little effect on collagen IV expression. This indicates
that MMP-7 is capable of degrading the tenascin-C produced
by these cells. The addition of a broad-spectrum inhibitor of
MMPs to LCDD-LC in culture media resulted in an increased
expression of tenascin-C, but not to the level of LCDD-LC
alone. A combination of LCDD-LC, MMP-7, and inhibitor II
showed expressions of tenascin-C similar to the LCDD-LC
MMP-1
Controla AL LCDD
MMP-3
MMP-7
b
MMP-1 (43 kDa)
MMP-3 (43 kDa)
MMP-7 (19 kDa)
Co
ntr
ol
MC
N
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DD
AL
Figure 10 | MMP-1, -3, and -7 expressions in HMCs cultured on
glass slides and treated with AL-LC, LCDD-LC, and controls. (a)
Note increased intracellular expressions of MMP-7 in LCDD-LC-
and AL-LC-treated cells as compared with controls, and the
absence of intracellular MMP-1 and MMP-3 expressions in all
treatment categories. (b) Western blot performed on the
conditioned media obtained from treated HMCs show stronger
bands for MMP-1 and MMP-3 in all categories compared with
MMP-7. In addition, AL-LC-treated cells show more intense bands
for all three MMPs. It can be noted that LCDD-LC-treated cells
show the least intense bands for MMP-7.
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alone treatment. This indicates that the inhibitor is capable of
inhibiting MMP-7 both exogenous and that produced by the
cells. Collagen IV remains localized to the periphery of the
nodules in all treatment conditions (Figure 5b). Excision of
these nodules from the matrix with subsequent harvesting
and the analysis of tenascin-C by ELISA showed similar
patterns as the immunohistochemistry (Figure 7). Quantita-
tive mRNA studies of the gene expressions of MMP-7 and
tenascin-C corroborate the protein expressions noted in all
the experimental conditions. Tenascin-C was noted to be
Control
MMP-7 MMP-7Tenascin-C Tenascin-C
Light chains only Light chains and tenascin-C
AL
LCDD
MCN
Control
AL
LCDD
MCN
a b
Figure 11 | MMP-7 and tenascin-C expressions in HMCs treated with different light chains and controls after 96 h incubation. Note
strong expression of tenascin-C in LCDD-LC-treated cells compared with lesser expressions in AL-LC-treated cells. Intracellular MMP-7
expressions were noted in all categories except MNC-LC-treated cells, with the highest expression in AL-LC-treated cells. Tenascin-C
deposition was significantly increased in LCDD-LC-treated cells compared with AL-LC-, myeloma cast nephropathy (MCN)-LC-treated cells,
and controls (a). The addition of exogenous tenascin-C with light chains to the HMCs resulted in the enhanced expression patterns of MMP-
7 in all categories. Tenascin-C expression and deposition were also significantly increased in all categories except AL-LC-treated cells as
compared with the untreated cells (b). Note the increased accumulation of intracellular MMP-7 and the accumulation of tenascin-C
extracellularly in LCDD, which appear as accentuated globules within the cytoplasm (red circles), original magnification  200.
Table 2 | MMP-7 and tenascin-C expressions in HMCs grown on glass slides in different experimental conditions
MMP-7 Tenascin-C
Mesangial cells Extracellular matrix Mesangial cells Extracellular matrix
(A) Light chain only
Control 2+ 1+ 0 0
AL 3+ 1+ 1+ 1+
LCDD 3+ 0 3+ 3+
MCN 1+ 1+ 0 1+
(B) Light chain and tenascin-C
Control 3+ 2+ 0 1+
AL 3+ 1+ 2+ 1+
LCDD 3+ 0 2+ 2+
MCN 3+ 2+ 2+ 1+
LCDD, light chain deposition disease; MCN, myeloma cast nephropathy.
(A) Intracellular and extracellular (matrix) expressions of both proteins were assessed after the incubation of cells with LCs and control only. (B) Similar assessment was made
on HMCs cultured in a parallel experiment, with the addition of exogenous tenascin-C.
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significantly upregulated in the LCDD-LC-treated cells as
compared with AL-LC-treated cells and controls. The
significant increase in tenascin-C gene expression when
exogenous MMP-7 and inhibitor are added to the LCDD-
LCs remains unclear (Figure 8a). MMP-7 gene is transcribed
in all treatment conditions (Figure 8b), and this coincides
with the intracellular protein expression and accumulation of
the enzyme. The analyses of tenascin-C and collagen IV in the
glomeruli from renal tissue showed results similar to the in
vitro analyses (Figure 9).
Although large amounts of MMP-7 are produced by the
mesangial cells treated with LCs (Figure 10a), the concentra-
tions of MMP-7 in the conditioned media are relatively small
(Figure 10b). It is unclear as to why mesangial cells are not
able to readily release MMP-7 into the conditioned media.
LCs might be toxic to the secretory mechanism of MMP-7 in
MCs by an unknown mechanism but also reduce MMP-7
mRNA production. This may be a key factor in the
accumulation of tenascin-C in the matrix in vitro and
in vivo in LCDD. In a paper addressing the pathogenesis of
diabetic nephropathy,48 it was shown that advanced glycation
end products (AGE) decrease MC MMP-7 production,
thereby playing a crucial role in mesangial matrix accumula-
tion. A similar scenario occurs in LCDD39 except that here
there is also an inability of MMP-7 release by the MCs,
especially when challenged by incubation with exogenous
tenascin. Figure 11b clearly shows the accumulation of MMP-
7 in the cytosol with accentuation underneath the cell
membranes in MCs. Treatment of MCs in vitro with
exogenous tenascin-C together with LCs resulted in the
stimulation of MMP-7 production and activation in some
treatment categories (Figure 11). This indicates that tenascin-
C is a substrate for MMP-7 and is capable of inducing the
expression, secretion, and activation of this MMP.
Glomerular injury
Type and severity of injury/host factors
Mesangial cells–smooth muscle phenotype
Mesangial cell
proliferation
ECM remodeling
Chronic
continuous
injury
G-LCs
LCDD-LCs
MMP
tenascin–C
TGP-β
Mesangial ECM
Mesangial nodule formation
Apo
ptos
is
MC myofibroblastic
transformation
LCs
PDGF-β
TGF-β
LCDD-LC
Acute
self-limiting
injury
Repair
Figure 12 | A schematic representation of the molecular events involved in the pathogenesis of LCDD. LCDD-LCs influence a
phenotypic transformation of MCs, and under the influences of PGDF-b and TGF-b, along with downregulated MMP expressions, produce
the characteristic LCDD lesion (nodular glomerulosclerosis).
Table 3 | Primer sequences for qRT-PCR
Gene Primer
Accession
number
GAPDH
Forward 50-GGAGTCAACGGATTTGGT-30 NM_002046
Reverse 50-GGCAACAATATCCACTTTACCAGA-30
MMP-7
Forward 50-TCCAGCGTTCATCCTCAT-30 NM_002423
Reverse 50-CAGGAAACACGCTGGCTCAT-30
Tenascin-C
Forward 50-CATCTCTGGAGGGGACCA-30 NM_002160
Reverse 50-CGGCCTCAGACCTGTGAGTGT-30
MMP-7, matrix metalloproteinase-7.
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It has been suggested that nodular glomerulosclerosis can
be reversed if the plasma cell dyscrasia can be controlled or
eradicated, but only a few anecdotal reports attest to this.49,50
Further research is needed to explore how the repair of the
damaged mesangium can be enhanced in an effort to
ultimately reverse the glomerular process in those patients
who have reached the stage of glomerulosclerosis.
The study presented here has shown that sequences of
events occurring in vivo leading to the mature stage of LC-
mediated LCDD can be recapitulated in vitro. Much of this
process is mediated through PDGF and TGF, and further
enhanced by the upregulation of tenascin-C and the
inhibition of MMP-7 release from transformed mesangial
cells. The process is summarized in Figure 12. The sequential
molecular events that have been elucidated and detailed in
this paper provide a number of opportunities for the design
of new therapeutic interventions that may avert the
progression of the disease or stimulate repair and/or
regression of the glomerular damage. A more rational
approach to treat renal damage in LCDD can be developed
to complement and enhance current therapy aimed exclu-
sively at controlling the production of LC by the neoplastic
plasma cells.
MATERIALS AND METHODS
Isolation and purification of LCs
Free LCs were purified from the urine of patients with known renal
biopsy-proven LCDD or AL-Am or myeloma cast nephropathy by a
series of affinity chromatography steps described in earlier
publications.10,27,38 Purified LCs from individual patients were used
for each of the experiments at a concentration of 10 mg/ml. LCs
obtained from different patients were not pooled for these
experiments.
Isolation of HMCs
HMCs were either isolated from unused kidney tissue that was
earmarked for transplantation or from normal areas of nephrectomy
tissue removed for neoplastic conditions. These mesangial cells were
cultured following Harpers procedure.51 Immunohistochemical
staining of cell cultures were positive for muscle-specific actin and
vimentin, whereas negative for keratin and factor VIII. Ultrastruc-
tural examination confirmed the presence of a homogeneous
population of mesangial cells. These mesangial cells were then
frozen at 80 1C and passaged for future experiments. P5 HMCs
were used in all experiments in this study.
Incubation of HMCs with LCs
HMCs were seeded onto eight-well tissue culture glass slides and
petri dishes, and then incubated in RPMI 1640 (Life Technologies-
Gibco, Grand Island, NY, USA) culture medium, and supplements
described earlier.39 They were allowed to grow to approximately
90% confluence with media change every 4 days, and later they were
brought to quiescence for 48 h with the same culture medium now
containing 0.05% fetal bovine serum (FBS). The cells were then
incubated in duplicate with LCs diluted (10 mg/ml) in phenol red-
free RPMI 1640 medium containing 0.05% FBS. HMCs cultured
with phenol red-free RPMI 1640 containing 0.05% FBS medium
devoid of LC served as controls. Cells were incubated for 96 h at
371C and 5% CO2 and 96% humidity. Cells and conditioned media
were harvested at the end of incubation. Cells were rinsed twice with
phosphate-buffered saline (PBS) (pH 7.4), fixed in 95% ethanol for
45 min, and then stored at 20 1C for future immunohistochemical
analyses. The conditioned media were collected in 2 ml microcen-
trifuge tubes and stored at 20 1C until needed.
Incubation of HMCs with LCs in 3D Matrigel
HMCs were cultured in Matrigel to create a 3D culture system using
35 mm petri dishes containing RPMI 1640 (Life Technologies-
Gibco) culture medium and supplements, as described earlier.39
Twelve 35 mm petri dishes were prepared for the study. The cells
were allowed to grow to approximately 90% confluence with media
change every 4 days. Two dishes were treated with an AL-LC (10 mg/
ml) in phenol red-free RPMI 1640 containing 0.05% FBS and two
with media alone. The remaining eight dishes were incubated with
an LCDD-LC (10 mg/ml) in phenol red-free RPMI 1640 containing
0.05% FBS. Three media changes containing the same concentration
of LCs were conducted every 4 days. After 12 days treatment,
duplicate dishes were treated as follows: control (media alone), AL
(10mg/ml AL-Am-LC), LCDD (10 mg/ml LCDD-LC),
LCDDþMMP-7 (10 mg/ml LCDD-LCþ 1 ml/ml (0.0005 U/ml) re-
combinant active human MMP-7 (Chemicon, Temecula, CA, USA),
LCDDþMMP inhibitor (10 mg/ml LCDD-LCþ 0.258 ml/ml (50 nM/
ml) Inhibitor II (EMD Chemicals, San Diego, CA, USA), and
LCDDþMMP7þMMP inhibitor (10 mg/ml LCDD-LCþ 1 ml/ml
(0.0005 U/ml) recombinant active human MMP-7þ 0.258 ml/ml
(50 nM/ml) inhibitor II). Conditioned media were harvested every 4
days and fresh media mixtures were added to the cells for 20 days.
Cells and conditioned media were harvested at the end of the
incubation period. The cells in Matrigel were placed in Tissue-Loc
Cassettes (Richard-Allan Scientific, Kalamazoo, MI, USA) and fixed
in 10% formalin. Cassettes were processed and embedded in paraffin
using routine histological protocol. Sections of 5mm thickness were
obtained from the cell blocks and processed for analysis by the various
staining methods, including routine H&E and immunohistochemical
techniques. The conditioned media were then collected in 2 ml
microcentrifuge tubes and stored at 20 1C until needed.
Isolation of mesangial nodules from Matrigel
Sections of 10 mm thickness were cut from paraffin-embedded
Matrigel cell blocks (described earlier) and floated onto non-plus
slides and allowed to air dry. A total of 400 nodules were
dissected from the sections with a 22-gauge hypodermic needle
and under a dissecting scope at  200 original magnification.
These were floated off in sterile PBS (pH 7.4), collected, and placed
in 2.0 ml Eppendorf tubes. Tubes were centrifuged at 2000 g for
5 min at 4 1C and the supernatant removed. A volume of 1 ml
TRIZOL Reagent (Invitrogen Corporation, Carlsbad, CA, USA) was
added to each pellet and proteins, and total RNA was harvested.
Quantities of tenascin-C were determined using an indirect ELISA
technique.
Total RNA and quantitative reverse transcriptase PCR for
MMP-7 and tenascin-C
Total RNA was extracted from tissue using TRIZOL. Total RNA
(5mm) was reversed transcribed to cDNA and quantitative reverse
transcriptase PCR was performed using the SYBR GreenER Two-
Step qRT-PCR Kit Universal (Invitrogen Corporation). Gene
expressions for GAPDH (glyceraldehyde 3-phosphate dehydrogen-
ase), MMP-7, and tenascin-C were examined using specific primers
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(Table 3). PCR results were expressed as a ratio of the target to
GAPDH amplicon.
Incubation of HMCs with LCs and exogenous tenascin-C
HMCs were seeded onto eight-well tissue culture glass slides and
grown under conditions described earlier.
The cells were then incubated in duplicate with an AL-LC,
LCDD-LC, or a myeloma cast nephropathy-LC diluted (10 mg/ml) in
phenol red-free RPMI 1640 containing 0.05% FBS with media alone
serving as controls. A parallel experiment was conducted with the
addition of 10 mg/ml human Tenascin-C-purified protein (Chemi-
con) to each treatment set described earlier. Cells were incubated for
96 h at 37 1C and 5% CO2 and 96% humidity. Cells and conditioned
media were harvested at the end of incubation. Cells were rinsed
twice with PBS (pH 7.4), fixed in 95% ethanol for 45 min, and then
stained for Tenascin-C and MMP-7 expressions using immunohis-
tochemistry.
Western blot on HMC-conditioned media
Samples were diluted in 4 LDS buffer (Invitrogen Life
Technologies, Carlsbad, CA, USA) to contain 90mg of total proteins
in 37 ml. Unknown samples, standard (10 ml recombinant human
MMP; R&D Systems Inc., Minneapolis, MN, USA), a and molecular
marker were loaded onto NuPAGE Novex 4–12% Bis-Tris (1.5 mm,
15 wells) gels (Invitrogen Life Technologies) and electrophoresed.
The gels were later transferred onto polyvinylidene fluoride (PVDF)
membranes by electrophoresis.
One mg/ml of primary MMP antibodies (R&D systems) was added
to the respective membranes and incubated at 4 1C overnight. The
membranes were then washed with Tris-buffered saline containing
0.05% polyoxyethylene sorbitan monolaurate (TTBS) at room
temperature and agitation. Diluted goat anti-mouse HRP-conjugated
(20 ml, 1:20 000; Jackson Laboratory, Bar Harbor, ME, USA)
secondary antibody was added to the membranes and incubated for
1 h at room temperature. The membranes were then washed four
times with TTBS and then placed in the Pierce Dura Signal (Pierce
Chemical, Rockford, IL, USA) detection reagent for 5 min each at
room temperature. X-ray films were used to capture images.
Immunohistochemical studies
Formalin-fixed and paraffin-embedded kidney tissues from renal
biopsies of patients with LCDD (n¼ 15), AL (n¼ 10), normal
(n¼ 15), diabetic nephropathy (n¼ 10), and HMCs grown in
Matrigel matrix were sectioned at 5 mm. The sections were
deparaffinized and rehydrated, and then moist heat antigen
retrieval.52 was performed on all sections except those for
tenascin-C for which Proteinase K (DakoCytomation, Carpinteria,
CA) digestion was used.
DAKO Peroxidase Blocking Reagent (DakoCytomation) endo-
genous peroxidase activity was followed by three washes with PBS
(pH 7.4). DAKO Protein Block Serum-Free (DakoCytomation) was
added to sections, followed by three washes with TTBS. Diluted
primary monoclonal antibody was added to the slides; monoclonal
anti-human MMP-1, -3, -7 antibody (1:20 dilution; R&D Systems,
Minneapolis, MN, USA), mouse anti-human tenascin-C antibody
(1:150 dilution; Novacastra Visonbiosystems, Newcastle Upon Tyne,
UK), mouse monoclonal anti-human collagen IV (1:40 dilution;
DakoCytomation), incubated at 4 1C overnight, and then rinsed
three times with TTBS. Peroxidase-labeled polymer (DakoCytoma-
tion) was added to each slide and incubated for 30 min at room
temperature. Sections were washed three times with TTBS, drained,
and diaminobenzidine (DAB) added. Sections were counterstained
with Harris’ hematoxylin for 10 s and then rinsed in running tap
water for 30 min. Sections were then prepared for microscopy. The
substitution of buffer as the primary antibody and universal
negative control mouse (DakoCytomation) added to these control
tissues served as negative controls.
Grading of immunohistochemical staining
Staining was graded on a numerical scale of 0–4 (where 0¼ negative
and 1–4 represented positive staining). Brown staining intensity was
assessed by comparison with the staining intensity of the nuclei
present in the samples. Grading was conducted by two investigators
independently and the results collated.
Indirect ELISA
A volume of 100ml of diluted antigen (200mg/ml total protein from
conditioned media, recombinant human proteins (positive control),
and buffer) was added in duplicate to wells of a 96-well ELISA plate
(BD Biosciences, Bedford, MA, USA) and incubated overnight at
4 1C. Plates were then washed three times with PBS (pH 7.4)
containing 0.05% polyoxyethylene sorbitan monolaurate (PBST). A
volume of 200ml 5% BSA was added to each well and incubated at
room temperature and agitation for 1 h, then rinsed with PBST three
times. A volume of 100ml of 1:500 diluted mouse monoclonal anti-
human tenascin clone BC-24 antibody (Sigma-Aldrich, St Louis,
MO, USA), 1:62.5 diluted mouse monoclonal anti-human PDGF-b
subunit antibody, and 1:250 diluted mouse monoclonal anti-human
LAP TGF-b1 antibody (R&D Systems) were added to each well of the
microtitre plate and incubated at room temperature and agitation for
2 h. Plates were then washed four times with PBST and 100ml of
1:100 000 diluted peroxidase-conjugated affinipure goat anti-mouse
IgG antibody (Jackson ImmunoResearch, Bar Harbor, ME, USA) was
added to each well. Plates were incubated for 2 h at room
temperature and agitation, and then washed four times with PBST.
A volume of 100ml of 3,30,5,50-tetramethylbenzidine substrate was
added to each well and incubated for 30 min at room temperature
and agitation, and then 25ml of 2 M H2SO4 was added to each well.
Absorbance was read at 450 nm using a Synergy 2 Multi-Detection
Microplate Reader (BioTek Instruments Inc., Winooski, VT, USA).
Statistical analysis
Quantitative data were expressed as means±s.d. and tested
statistically using the unpaired t-test. All P-values quoted were
two-tailed at a confidence level of 0.95. The Wilcoxon sum-ranked
test for nonparametric two-way analysis of variance at a confidence
interval of Po0.05 was used for qualitative data.
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